progression free survival

Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...

Shanghai, China | March 21, 2026 Dizal has announced positive topline results from its multinational Phase 3 WU-KONG28 clinical...

South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...